Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect

Recent FDA Drug Safety Communications report an increased risk for acute kidney injury in patients treated with the gliflozin class of sodium/glucose co-transport inhibitors indicated for treatment of type 2 diabetes mellitus. To identify a potential rationale for the latter, we used an in vitro hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Secker, Philipp F., Beneke, Sascha, Schlichenmaier, Nadja, Delp, Johannes, Gutbier, Simon, Leist, Marcel, Dietrich, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833677/
https://www.ncbi.nlm.nih.gov/pubmed/29445145
http://dx.doi.org/10.1038/s41419-018-0273-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833677/
https://www.ncbi.nlm.nih.gov/pubmed/29445145
http://dx.doi.org/10.1038/s41419-018-0273-y

Ejemplares similares